1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA

作者：T. John, T-E. Ciuleanu, M. Cobo Dols, M. Schenker, B. Zurawski, J. Menezes, E.A. Richardet, J. Bennouna, Y. Cheng, E. Felip, Óscar Juan, A. Alexandru, L. Paz-Ares, S. Lu, M. Reck, N. Hu, X. Zhang, D.J. Grootendorst, L. Eccles, D.P. Carbone · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.07.1175 · 被引用次数：3 · 研究领域：Cancer Immunotherapy and Biomarkers、Advanced Breast Cancer Therapies、Colorectal Cancer Treatments and Studies